Tobacco remains the leading preventable cause of death in the United States, and disproportionately affects people with mental illness. E-cigarette use is increasing in the United States and people with mental illness are reporting use that is greater than the general population. Psychiatrists are being faced with questions about use and risks regularly or are often unsure what to recommend to patients. This webinar will summarize tobacco use among those with mental illness, discuss e-cigarettes, and summarize the most recent recommendations on risks and safety. Currently, there are seven FDA-approved medications for tobacco cessation (nicotine replacement therapies (gums, patches, lozenges, inhaler, nasal spray), bupropion and varenicline. Using varenicline in patients with serious mental illness can be done safely with proper monitoring for psychiatric side effects. When medications are combined with psychosocial treatments such as a tobacco cessation group, individual therapy or a structured tobacco cessation program, quit rates from tobacco can rise up to nearly 40% or higher.